​

Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

AVTX Stock Forecast

Avalo Therapeutics (AVTX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $25.00, with a high of $25.00 and a low of $25.00. This represents a 36.02% increase from the last price of $18.38.

- $5 $10 $15 $20 $25 High: $25 Avg: $25 Low: $25 Last Closed Price: $18.38

AVTX Stock Rating

Avalo Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 1 Hold (20.00%), 1 Sell (20.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 1 3 Strong Sell Sell Hold Buy Strong Buy

AVTX Price Target Upside V Benchmarks

TypeNameUpside
StockAvalo Therapeutics36.02%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$25.00$24.00
Last Closing Price$18.38$18.38$18.38
Upside/Downside-36.02%30.58%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2527---9
Sep, 2526---8
Aug, 2525---7
Jul, 2526---8
Jun, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 17, 2025H.C. Wainwright$25.00$11.33120.65%36.02%
Mar 25, 2025Kambiz YazdiJefferies$23.00$8.54169.32%25.14%
Apr 16, 2024Leland GershellOppenheimer$35.00$15.24129.66%90.42%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2025H.C. WainwrightBuyBuyhold
Sep 05, 2025Cowen & Co.Buyinitialise
Aug 15, 2025Cantor FitzgeraldOverweightinitialise
Mar 25, 2025JefferiesUnderperformBuyinitialise
Feb 28, 2025Piper SandlerOverweightinitialise
Dec 19, 2024BTIGBuyinitialise
Oct 24, 2024H.C. WainwrightNeutralinitialise
Aug 15, 2024OppenheimerOutperformOutperformhold
Apr 16, 2024OppenheimerOutperformupgrade
Jun 27, 2023StephensEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-600 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.52K$-2.33K$-1.06K$-113.58$-4.32----
Avg Forecast$-2.28K$-2.26K$-698.40$-96.00$-25.79$-5.31$-4.30$-4.48$-3.08
High Forecast$-2.28K$-2.26K$-691.71$-96.00$-2.22$-5.10$-1.66$-4.48$-3.08
Low Forecast$-2.28K$-2.26K$-711.78$-96.00$-49.35$-5.51$-6.35$-4.48$-3.08
Surprise %10.93%3.22%52.15%18.31%-83.25%----

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.70M$5.40M$18.05M$1.92M$441.00K----
Avg Forecast$5.20M$6.08M$20.80M$1.70M$150.00K$1.00M$1.00M$1.00M$1.71M
High Forecast$5.20M$6.08M$21.10M$1.70M$163.04K$1.00M$1.00M$1.00M$1.71M
Low Forecast$5.20M$6.08M$20.64M$1.70M$130.43K$1.00M$1.00M$1.00M$1.71M
Surprise %28.83%-11.28%-13.20%13.18%194.00%----

Net Income Forecast

$-650M $-520M $-390M $-260M $-130M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.38M$-84.35M$-41.66M$-31.54M$-35.13M----
Avg Forecast$-631.89M$-627.09M$-193.97M$-26.66M$-8.13M$-1.47M$-1.11M$-1.24M$-854.01K
High Forecast$-631.89M$-627.09M$-192.11M$-26.66M$-615.98K$-1.42M$-461.46K$-1.24M$-854.01K
Low Forecast$-631.89M$-627.09M$-197.68M$-26.66M$-13.71M$-1.53M$-1.76M$-1.24M$-854.01K
Surprise %-89.81%-86.55%-78.52%18.31%331.83%----

AVTX Forecast FAQ

Is Avalo Therapeutics stock a buy?

Avalo Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Avalo Therapeutics is a favorable investment for most analysts.

What is Avalo Therapeutics's price target?

Avalo Therapeutics's price target, set by 5 Wall Street analysts, averages $25 over the next 12 months. The price target range spans from $25 at the low end to $25 at the high end, suggesting a potential 36.02% change from the previous closing price of $18.38.

How does Avalo Therapeutics stock forecast compare to its benchmarks?

Avalo Therapeutics's stock forecast shows a 36.02% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Avalo Therapeutics over the past three months?

  • October 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Avalo Therapeutics’s EPS forecast?

Avalo Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.31, marking a 22.92% increase from the reported $-4.32 in 2024. Estimates for the following years are $-4.3 in 2026, $-4.48 in 2027, and $-3.08 in 2028.

What is Avalo Therapeutics’s revenue forecast?

Avalo Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1M, reflecting a 126.76% increase from the reported $441K in 2024. The forecast for 2026 is $1M, followed by $1M for 2027, and $1.71M for 2028.

What is Avalo Therapeutics’s net income forecast?

Avalo Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-1.474M, representing a -95.80% decrease from the reported $-35.129M in 2024. Projections indicate $-1.113M in 2026, $-1.244M in 2027, and $-854K in 2028.